盐酸埃克替尼治疗45例晚期非小细胞肺癌的临床疗效分析  

Clinical Efficacy of Icotinib Hydrochloride for 45 Cases with Advanced Non-small Cell Lung Cancer

作　　者：王云[1] 蒋雪[1] 王莹[1] 

机构地区：[1]皖南医学院第一附属医院,安徽芜湖241000

出　　处：《肿瘤学杂志》2016年第3期176-179,共4页Journal of Chinese Oncology

摘　　要：[目的]探讨盐酸埃克替尼治疗晚期非小细胞肺癌（NSCLC）的临床疗效及不良反应。[方法 ]回顾性分析45例经病理学确诊的晚期NSCLC患者临床资料及埃克替尼治疗的临床疗效和不良反应。所有患者均口服盐酸埃克替尼片,125mg/次,3次/d,直至病情进展或出现不能耐受的不良反应。[结果]45例患者治疗1个周期后,完全缓解（CR）0例,部分缓解（PR）20例（44.4%）,疾病稳定（SD）15例（33.3%）,疾病进展（PD）10例（22.2%）,客观有效率（ORR）为44.4%（20/45）,疾病控制率（DCR）为77.8%（35/45）,中位无进展生存期（m PFS）为6.3个月（95%CI：3.6~9.0）,中位总生存期（m OS）为15.2个月（95%CI：11.3~19.0）。治疗相关不良反应主要为皮疹4例（8.9%）,腹泻及胃部不适2例（4.4%）,肝功能损害2例（4.4%）。盐酸埃克替尼治疗的疗效与吸烟史有关（P〈0.05）。[结论]盐酸埃克替尼治疗晚期NSCLC疗效肯定,具有毒性低、安全性高、耐受性好的特点,作为新的表皮生长因子受体—酪氨酸激酶抑制剂,为晚期NSCLC患者的治疗提供了新选择。[Purpose] To investigate the efficacy and toxicities of icotinib hydrochloride in the treatment of patients with advanced non-small cell lung cancer（NSCLC）. [Methods] The clinical data,efficacy and toxicities of icotinib hydrochloride in the treatment of 45 cases with advanced NSCl C were analyzed retrospectively.Patients were treated with icotinib hydrochloride（125mg,3times a day） untill disease progression or intolerance with toxicities. [Results] After one period of treatment,zero cases showed compelet response（CR）;20 cases（44.4%）showed partial response（PR）;15 cases（33.3%） achieved stable disease（SD）;and 10 cases（22.2%）had progressive disease（PD）.The objective response rate（ORR） was 44.4%（20/45）,and disease control rate（DCR） was77.8%（35/45）.The media progression free survival（m PFS） was 6.3 months,and the media overall survival（m OS） was 15.2 months. The major toxicities were skin rash（4 cases,8.9%）,diarrhea and stomach upset（2 cases,4.4%）.Two patients had liver damage（4.4%）.The efficacy of icotinib hydrochloride was associated with the smoking history（P0.05）.[Conclusion] Icotinib hydrochioride is effective in the treatment for advanced NSCLC,with low toxicity,good safety and tolerability.As a new epidermal growth Factor receptor-tyrosine kinase inhibitor（EGFR-TKI）,it provides a new choice for patients with advanced NSCLC.

关 键 词：非小细胞肺癌 盐酸埃克替尼 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]